mFast-SeqS-based aneuploidy score in circulating cell-free DNA is a prognostic biomarker in prostate cancer.
Sign Up to like & getrecommendations! Published in 2023 at "Molecular oncology"
DOI: 10.1002/1878-0261.13449
Abstract: Multiple prognostic biomarkers, including circulating tumor cell (CTC) counts, exist in metastatic castration-resistant prostate cancer (mCRPC) patients, but none of them have been implemented into daily clinical care. The modified fast aneuploidy screening test-sequencing system… read more here.
Keywords: dna; cell free; mcrpc patients; aneuploidy score ... See more keywords
Prostate cancer: AR-Vs not predictive in mCRPC
Sign Up to like & getrecommendations! Published in 2018 at "Nature Reviews Urology"
DOI: 10.1038/nrurol.2018.24
Abstract: receptor splice variant 7 or 9 in whole blood does not predict response to androgen-axis–targeting agents in metastatic castration-resistant prostate cancer. Eur. Urol. https://doi.org/ 10.1016/j.eururo.2018.01.007 (2018) FURTHER READING Attard, G. & Antonarakis, E. S. Prostate… read more here.
Keywords: prostate; mcrpc; response; prostate cancer ... See more keywords
The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population.
Sign Up to like & getrecommendations! Published in 2021 at "Prostate cancer and prostatic diseases"
DOI: 10.1038/s41391-021-00344-1
Abstract: BACKGROUND In 2004 docetaxel was the first life-prolonging drug (LPD) registered for metastatic castration-resistant prostate cancer (mCRPC) patients. Between 2011 and 2014 new LPDs for mCRPC (cabazitaxel, abiraterone, enzalutamide, and radium-223) were introduced in the… read more here.
Keywords: mcrpc; subgroup; mcrpc patients; prostate cancer ... See more keywords
Identification of patients with metastatic castration-sensitive or metastatic castration-resistant prostate cancer using administrative health claims and laboratory data
Sign Up to like & getrecommendations! Published in 2021 at "Current Medical Research and Opinion"
DOI: 10.1080/03007995.2021.1879753
Abstract: Abstract Objective To develop algorithms to identify metastatic castration-sensitive prostate cancer (mCSPC) patients and castration-resistant prostate cancer (mCRPC) patients, using health claims data and laboratory test results. Methods A targeted literature review summarized mCSPC and… read more here.
Keywords: mcrpc; health claims; prostate cancer; metastatic castration ... See more keywords
PO-348 Two novel synthetic analogues of miR-1207–3 p, NB5 and NB1207, target AR-V7 and C-MYC and demonstrate in vivo therapeutic efficacy in metastatic castrate-resistant prostate cancer (mCRPC)
Sign Up to like & getrecommendations! Published in 2018 at "ESMO Open"
DOI: 10.1136/esmoopen-2018-eacr25.860
Abstract: Introduction Chromosome 8q24 prostate cancer (PCa) susceptibility region encodes miR-1207–3 p which directly targets fibronectin type III domain containing 1 (FNDC1) to regulate fibronectin (FN1) and subsequently the androgen receptor (AR), and FNDC1/FN1/AR is overexpressed in… read more here.
Keywords: mcrpc; prostate; pca; expression ... See more keywords
Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-19-2303
Abstract: Purpose: The purpose of this study was to measure genomic changes that emerge with enzalutamide treatment using analyses of whole-genome sequencing and RNA sequencing. Experimental Design: One hundred and one tumors from men with metastatic… read more here.
Keywords: mcrpc; enzalutamide resistant; number loss; loss ... See more keywords
Abstract 4063: Target immunosuppressive myeloid cells to enhance cancer immunotherapy
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-4063
Abstract: A significant fraction of advanced prostate cancer (PCa) patients treated with androgen deprivation therapy (ADT) experience relapse with relentless progression to lethal metastatic castration-resistant prostate cancer (mCRPC). Immune checkpoint blockade (ICB) using antibodies against cytotoxic-T-lymphocyte-associated… read more here.
Keywords: mcrpc; immunotherapy; target immunosuppressive; cancer ... See more keywords
Abstract 4104: Development of adoptive T-cell therapies to target heterogeneity of mCRPC
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-4104
Abstract: Metastatic castration resistant prostate cancer (mCRPC) remains a significant challenge with limited durable therapeutic responses, and innovative and effective treatment strategies are needed. Advanced mCRPC often comprises a heterogeneous population of prostate adenocarcinoma (PrAd) and… read more here.
Keywords: cell; prad; car; mcrpc ... See more keywords
Abstract 519: A novel Skp1 inhibitor has potent preclinical efficacy against metastatic castration-resistant prostate cancer
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-519
Abstract: Purpose: Despite numerous therapeutic modalities, including chemotherapy and next-generation androgen deprivation therapy, metastatic castration-resistant prostate cancer (mCRPC) remains a dreadful evolution and still bears a poor prognosis for most patients who develop metastases to bones… read more here.
Keywords: cell; prostate cancer; skp1; mcrpc ... See more keywords
Abstract 5614: Genomic aberrations in circulating tumor DNA (ctDNA) and clinical outcomes from [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC)
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-5614
Abstract: [177Lu]Lu-PSMA-617 (LuPSMA) radionuclide therapy improves overall survival in mCRPC, and was recently approved by the FDA. Nevertheless, owing to the heterogeneous nature of mCRPC, responses to LuPSMA therapy can be variable, and resistance is inevitable.… read more here.
Keywords: ctdna; psa pfs; variant; mcrpc ... See more keywords
Abstract CT159: CYCLONE 1: abemaciclib in men with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC)
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-ct159
Abstract: Background: Treatment options for patients (pts) with heavily pretreated mCRPC are limited. Augmenting endocrine therapy by targeting CDK4/6 with abemaciclib has dramatically improved outcomes in HR+ breast cancer. Similar to ER, AR signaling activates CDK4… read more here.
Keywords: prostate cancer; heavily pretreated; abemaciclib; mcrpc ... See more keywords